IMRN News and Press, Immuron Limited From 03/07/24

2024-03-07 09:09:27 ET CERo Therapeutics ( CERO ) +625% after announces publication of preclinical research supporting the use of its clinical candidate CER-1236 to treat AML patients . Lytus Technologies ( LYT ) +210% after enters $326 billion data center market...

2024-03-07 07:13:09 ET More on Immuron Financial information for Immuron Read the full article on Seeking Alpha For further details see: Immuron surges after mid-stage data for antidiarrheal med

2024-03-07 06:52:16 ET DENVER, Colo., Mar 07, 2024 ( 247marketnews.com )- Immuron Limited (NASDAQ: IMRN ) reported, this morning, that the interim topline results confirm that a single daily dose of Travelan is effective in prevention of moderate to severe diarrhea following challen...

Highlights: Immuron proceeding to Phase 3 registration strategy with the FDA Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose 36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induc...

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Fes...

2024-02-13 07:37:39 ET More on Immuron Financial information for Immuron Read the full article on Seeking Alpha For further details see: Immuron up 3% on record Travelan sales

Highlights: Travelan ® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 million Australian Travelan ® YTD Jan 2024 sales $2.1 million USA Travelan ® YTD Jan 2024 sales $0.6 million Canadian sales recommenc...

Highlights: Record half yearly Travelan ® sales of $2,334,969 Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales 51% higher than pre-pandemic period H1, FY20 sales MELBOURNE, Australia, Jan. 16, 2024 (GLOBE NEWSW...

Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been completed Pre-IND submission to the U.S. Food and Drug adm...

Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunteers against moderate to severe campylobacteriosis New CampETEC pro...